Curaleaf Holdings, Inc. (CURLF)

Price$9.92Cached quoteAs of 2026-09-05 05:18 UTC

AI: Overvalued

Price checkThe market price demands stronger cash growth than Curaleaf has consistently delivered.

At the observed price, equity is worth about $2.63 billion. Adding supplied June net debt near $815 million values the operating business around $3.44 billion. That is roughly 13 times annualized first-half management-adjusted operating earnings before interest, tax, and noncash charges, and about 35 times 2025 free cash flow. Free cash flow is cash left after operations and investment. Those are demanding multiples for a leveraged company with recurring annual losses, so the shares look overvalued absent much better cash conversion.

Big pictureSales have resumed growing, but reported profits still depend on unusual tax benefits.

Revenue slipped 5% in 2025 and remained below 2023, showing the earlier expansion cycle had stalled. Second-quarter 2026 revenue then rose 10% to $340 million; international revenue rose 26% to $51 million, and gross profit reached 50% of sales. Yet operating income was only $4 million, while the $12.5 million net profit included a $38.8 million tax benefit. This rebound is encouraging, but state-by-state cannabis openings and wholesale pricing make demand uneven, and management-adjusted operating profitability still declined from the prior year.

Business strengthPositive cash generation helps, yet costly debt and share growth weaken shareholder protection.

Operations produced $138 million of cash in 2025, while capital spending used $63 million, leaving $74 million. First-half 2026 free cash flow slowed to $17 million. Supplied June figures show $95 million cash against $909 million total debt, though current assets exceeded near-term liabilities by $161 million. February’s refinancing pushed $500 million to 2029 but carries an 11.5% rate. Shares increased 7% from year-end 2024 to June 2026; a $7.4 million repurchase barely offset stock compensation and continuing dilution.

What could change the storySustained cash growth could justify optimism, while the Aurora bid adds execution risk.

A stronger case needs several quarters near recent 8%–10% sales growth, stable 50% gross profitability, annual free cash flow above roughly $100 million, and declining net debt. International growth offers the clearest upside. Conversely, the Aurora proposal could issue up to 24 million Curaleaf shares—about 9% of June shares—and use roughly $52 million cash before integration costs. Aurora’s medical assets and cash could add value, but its board rejected the offer and Curaleaf designed it without private due diligence. Failure to lift per-share cash flow would reinforce the bear case.

AI: News

Second-quarter reboundQuarterly sales recovered, but tax benefits and weak cash conversion temper the profit headline.

On August 5, Curaleaf reported second-quarter revenue of $340.1 million, up 10% year over year, and net income of $12.5 million versus a prior-year loss. International sales rose 26%. However, the profit included a $38.8 million tax benefit, and first-half free cash flow was only $17.4 million. CURLF gained 10.42% in the next session; the timing is consistent with a favorable earnings response but does not prove the report alone caused the move.

Aurora bid launchedThe proposed Aurora purchase offers international scale but would issue shares and spend scarce cash.

Curaleaf formally launched the offer on August 18 after announcing its intent on August 11. Each Aurora share would receive 0.3463 Curaleaf shares plus $0.75 cash. Full acceptance could require about 24 million new Curaleaf shares and roughly $52 million cash. Management sees international manufacturing and distribution benefits, but the offer was built from public information without private due diligence. The December 1 expiry leaves the outcome, integration costs, and effect on value per Curaleaf share uncertain.

Aurora board rejects bidAurora’s rejection raises the odds of a failed bid or more expensive terms.

On September 2, Aurora’s board unanimously recommended shareholders reject the bid, calling it inadequate and highlighting Curaleaf’s costly debt and tax uncertainty. Aurora reported about $149 million of cash and no debt under its definition. That cash could make Aurora strategically attractive and strengthen its bargaining position; this is an inference. The rejection does not end the offer, but it raises the possibility of a failed bid, extended contest, or richer terms. Any stock effect cannot be cleanly separated from broader cannabis-sector trading.

Loading local price history

Revenue

2019

2020

2021

2022

2023

2024

2025

Net income

2019

2020

2021

2022

2023

2024

2025

Free cash flow

2019

2020

2021

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2019

2020

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021	2020	2019
Revenue	$1.27B	$1.33B	$1.35B	$1.28B	$1.20B	$626.6M	$221.0M
Gross profit	$631.0M	$640.8M	$614.4M	$626.4M	$569.8M	$390.5M	$141.6M
Gross margin	49.76%	48.02%	45.63%	49.11%	47.65%	62.32%	64.07%
Research & development	$805,000	$1.4M	$1.4M	—	—	—	—
Operating expenses	$605.6M	$616.0M	$571.6M	$561.4M	$511.3M	$318.1M	$169.3M
Operating income	$25.4M	$24.7M	$42.9M	$65.0M	$58.6M	$72.4M	−$27.7M
Operating margin	2.01%	1.85%	3.18%	5.10%	4.90%	11.56%	−12.54%
EBITDA	$222.1M	$256.2M	$238.8M	$221.0M	$179.1M	$132.4M	$4.0M
EBITDA margin	17.51%	19.20%	17.73%	17.32%	14.98%	21.12%	1.80%
Net income	−$231.1M	−$215.4M	−$281.2M	−$370.1M	−$205.9M	−$56.8M	−$69.8M
Net profit margin	−18.22%	−16.15%	−20.88%	−29.02%	−17.22%	−9.06%	−31.60%
Basic EPSper basic share	-$1.06	-$0.97	-$1.18	-$1.58	-$0.88	-$0.30	-$0.45
Diluted EPSper diluted share	-$1.06	-$0.97	-$1.18	-$1.58	-$0.88	-$0.30	-$0.45

Review official source filings ↗

Owners

Reported shareholders

Ownership data is not available for this listing yet.

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)0$0.00 disclosed value

No insider transactions transactions were reported in the stored SEC coverage.

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about CURLF yet. Start the conversation.

Write the first post

Curaleaf Holdings, Inc. (CURLF)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.